Organogenesis competitors

Michael 'Mike' Cotton is a Regional Chief Executive Officer at UnitedHealthcare Community & State, President/CEO at ALERE HEALTH, and Board Member at BioIQ Inc and is based in Atlanta Metropolitan Area. He has worked as Chief Operating Officer- QualChoice Health Plan at University Hospitals, President/CEO at SelectHealth Inc, and Managing Director at Mercer Human Resources Cnsltng. Michael works or has worked at Matria Healthcare and works or has worked as Senior VP/COO at Univ Hospitals Health Systems. He attended The Ohio State University, FRANKLIN UNIVERSITY, and Cleveland State University.

Mr. Mazelsky was appointed President and Chief Executive Officer of IDEXX on October 23, 2019. Prior to his appointment, Mr. Mazelsky served as IDEXX's Interim President and Chief Executive Officer beginning on June 28, 2019. Prior to his appointment as Interim President and Chief Executive Officer, he was an Executive Vice President responsible for our North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including our IDEXX VetLab® in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business. He joined IDEXX in August 2012 as Executive Vice President. Previously, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics. Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent’s Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit from 1997 to 2000 at Agilent Technologies. From 1988 to 1996, he was in a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds a bachelor’s degree in mathematics from the University of Rochester and an M.B.A. from the University of Chicago.

Timothy R. Wright is the President and CEO of M2Gen®. He was previously the Executive Vice President, Business Development, Strategy and Innovation at Teva. Mr. Wright is the founder and Chairman of the Drug Discovery and Development Institute for The Ohio State University Comprehensive Cancer Center, where he previously served as Director. He is a current a member of the Ohio State Innovation Foundation Board and the Ohio State School of Pharmacy External Advisory Board. Mr. Wright has served in executive leadership roles at several pharmaceutical firms, including Covidien, Elan, and DuPont Merck. He holds a B.Sc. from The Ohio State University.

Jonathan Kennedy has served as Chief Executive Officer and Director of Natus since July 2018. Prior to his appointment as CEO, Mr. Kennedy served as the Company’s Chief Financial Officer since April 2013 and served as General Manager of Natus’ Newborn Care Business Unit from April 2017 to February 2018. Before joining Natus, Mr. Kennedy was Chief Financial Officer of Intersil Corporation, a global semiconductor manufacturer, since 2009. Prior to that, he was Intersil’s Corporate Controller since 2005. Before joining Intersil, Mr. Kennedy held management roles in Finance and Information Technology with Alcon Inc., a manufacturer of medical devices and pharmaceuticals for the ophthalmic industry and Harris Corporation, a diversified global technology company. Mr. Kennedy served on the Board of Directors of Iradimed Corporation a manufacturer of MRI compatible medical devices from 2016 to 2019. He holds a Bachelor of Science degree in Business Administration and a Master of Science degree in Accounting from the University of Central Florida.

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors. Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

Geoff Martha is firmly establishing Medtronic as the undisputed global leader in healthcare technology. As chairman & CEO, Geoff leads the $30 billion company and its 90,000 employees in pursuit of fulfilling the Medtronic Mission to use technology to improve human welfare. He is recognized as a driven and innovative executive - ranking in Modern Healthcare’s 100 Most Influential People in Healthcare in 2020 and listed as the #1 CEO in healthcare technology by the Healthcare Technology Report in 2021.Geoff became CEO in April 2020. Under his leadership, Medtronic is putting the ‘tech’ in MedTech, leveraging the latest advances in cutting edge technology to transform healthcare. Fortune Magazine named Medtronic among the top 15 companies for its 2020 “Change the World” list, recognizing its swift efforts during the pandemic, and listed the company on its 2021 list of Most Admired Companies.Geoff joined Medtronic in 2011, and notably led the acquisition and integration of Covidien, the largest acquisition in the medical technology industry. Before joining Medtronic, Geoff spent 19 years at GE Healthcare and GE Capital.Geoff is a member of the Business Roundtable, and the World Economic Forum’s International Business Council. He also co-chairs the Taskforce on Health and Life Sciences for B20, a G20 engagement group.An ardent supporter of philanthropic and diversity initiatives, Geoff serves on the board of directors for the Medtronic Foundation, Children’s HeartLink, and the Northside Achievement Zone. He is part of OneTen, a coalition of cross-industry leaders committed to breaking down systemic barriers for Black Americans. He also serves as Medtronic’s Executive Sponsor to FIRST Robotics.Geoff received a bachelor’s degree in Finance from Pennsylvania State University, where he currently serves on the Development Council for its College of Liberal Arts. He was also captain of the Penn State men’s hockey team and later inducted into its Hockey Hall of Fame.

Chris Reinhard is a Chief Executive Officer at Activation Therapeutics Inc, Chief Executive Officer (formerly Collateral Therapeutics) at Angiogonetics Therapeutics, and Chief Executive Officer at LifeAgain Advanced Medical Data Analytics and is based in San Diego, California. He has worked as Managing Director & Vice President at Henley Group; Chief Executive Officer at InnerCool Therapeutics, Inc.; and Assistant Treasurer / Director Special Projects at Signal AI.

Eugene Lopez is a CEO at Innovative Concepts and Owner at Party Concepts and is based in Dallas/Fort Worth Area. He has worked as General Market Manager at Entertainment Marketing Inc. Eugene attended St John's University between 1983 and 1986.